Teva Director Vigodman’s Name Floated As New CEO
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva’s next CEO may be Erez Vigodman, who has served on Teva’s board since 2009 and is CEO of the generic crop protection company Makhteshim Agan. Whether the appointment of an existing director with limited pharmaceutical experience will appease investors calling for broader change remains to be seen.
You may also be interested in...
Teva CEO Steps Down While An Integration Hangs In The Balance
After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.
Teva CEO Steps Down While An Integration Hangs In The Balance
After a damaging court ruling on Copaxone 40 mg and some management missteps, CEO Erez Vigodman will step down as CEO of the Israeli generic drug leader. Chairman Yitzhak Peterburg will fill in on an interim basis.
Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.